Article images may contain Chinese text.
As a vice-president member of the China Association of Pharmaceutical Commerce, Weiming Penguin has long been deeply involved in industry development, building extensive expertise and broad recognition in pharmaceutical digital transformation. At the 2025 Pharmaceutical Distribution Industry Information Conference and Pharmaceutical Distribution Innovation Conference, Weiming Penguin co-founder and president Tian Ying was invited to attend in person. In addition to participating in important sessions, she joined a high-level roundtable at a key subforum to speak on behalf of the company.
Major Conference HighlightsThis high-profile conference was held from August 27 to 29, 2025, at the InterContinental Hangzhou International Conference Center, bringing together government and corporate representatives, experts, and scholars from across China’s pharmaceutical distribution sector. The main forum on August 28 featured numerous highlights: Shi Yigong, an academician of the Chinese Academy of Sciences and president of Westlake University, delivered a presentation titled “Frontier Discoveries and Challenges in Biomedicine,” offering an in-depth analysis of directions for technological breakthroughs in the industry. Officials from the Ministry of Commerce’s Department of Market Operation and Consumption Promotion released pharmaceutical distribution industry data covering 2024 through the first half of 2025, providing an authoritative data reference for industry development. The conference also included important events such as the launch of work to formulate guidelines for pharmaceutical distribution industry development during the 15th Five-Year Plan period and the release of a pharmaceutical industry compliance consensus, setting the direction for the industry’s future development.
Key Roundtable DiscussionAt the concurrent “Third Artificial Intelligence Applications Conference and Pharmaceutical Supply Chain Conference” subforum, the high-level dialogue on “In-Depth Applications and Innovative Practices of AI and Digitalization in the Pharmaceutical Industry” became a focal point. Moderated by Dong Fengjian, deputy general manager of China Resources Pharmaceutical Commercial Group Co., Ltd., the session brought together Weiming Penguin co-founder & president Tian Ying and seasoned industry professionals: Xu Youheng, vice president of Guangzhou Pharmaceuticals Co., Ltd.; Mao Jun, deputy head of the Information Department at Jointown Pharmaceutical Group Co., Ltd.; Qin Jian, director of the Digital Intelligence Center at China General Technology Group’s Chongqing Pharmaceutical Holding Co., Ltd.; Ma Yuntao, director of Digital Innovation at Nanjing Pharmaceutical Co., Ltd.; and Chen Yong, head of Pfizer’s Digital China Delivery Center. Drawing on Weiming Penguin’s practical experience in pharmaceutical digital transformation, President Tian shared specific use cases for AI in pharmaceutical channel management and supply chain optimization. Her discussion of improving business efficiency through data and addressing industry pain points with intelligent tools resonated widely with attendees. Based on Weiming Penguin’s own practical experience in pharmaceutical digital transformation, Tian Ying shared three foundations for success in the AI era:A data foundation with an adequate level of quality and efficiency,
A knowledge base supported by lifecycle management,
An underlying system with flexible integration interfaces
Three Key Principles for Success in the AI Era:
Business first: Study the business, understand it in depth, and stay close to it.
Cross-disciplinary talent: The scarcest talent is people who can use the right technology to solve the appropriate business problems.
Make the most of what you have: Often, the task is to address data silos and combine internal and external company knowledge, rather than rebuild a whole collection of systems. Flexibility, collaboration, and reintegration are therefore also effective ways to approach the problem.
Responsibility, Mission, and CommitmentAs a vice-president member of the China Association of Pharmaceutical Commerce, Weiming Penguin has always regarded advancing digital transformation in the pharmaceutical industry as its responsibility.Weiming Penguin actively contributes advice and recommendations to the China Association of Pharmaceutical Commerce and received recognition for a 2025 Benchmark Case in Pharmaceutical Industry Digital Transformation. At this awards ceremony, the company received its award in person from Shi Shengyi, president of the China Association of Pharmaceutical Commerce. This reflects the association’s strong recognition of and attention to our work, as well as the solid foundation of collaboration the two sides have built over the years.Leveraging its technological strengths in AI algorithms and big data analytics, Weiming Penguin has provided customized digital solutions to multiple pharmaceutical companies—from monitoring pharmaceutical distribution data and issuing channel risk alerts to intelligently managing outlet sales—helping companies reduce operating costs and respond to markets more quickly. Participating in this conference demonstrated Weiming Penguin’s commitment to fulfilling its responsibilities as an association member and contributing to industry development. It also provided an important opportunity for the company to share its digital transformation experience with the industry and build consensus on future development.The pharmaceutical industry is accelerating its shift toward digitalization and intelligent operations, with AI becoming a core driver of industry advancement. If your company faces challenges such as difficult channel management, low data utilization, or a lack of direction in digital transformation, visit the Weiming Penguin website (www.tenez.cn) to learn more about our solutions, or follow our official WeChat account (wmpenguin) for the latest industry insights. For partnership inquiries, call our dedicated service hotline at 137-1791-5751 (staffed on business days from 9:00–18:00). We will provide one-on-one professional support as we explore effective paths to AI-powered digital transformation for pharmaceutical companies together.